TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05197270: 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Sponsor: 4D Molecular Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 215 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,172,940

Rescue Site Savings

+$1,439,220

Unlock Full NCT05197270 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05197270 Rescue Dossier →